09:47 AM EST - BioVaxys Technology Corp. : Announced today that it is assessing steps to modify BVX-0320 and Covid-T, its SARS-CoV-2 vaccine candidate and T-cell diagnostic, to address the newly emerging variants (the South African, UK, and Brazilian variants) of SARS-CoV-2 that are of high concern to worldwide governments, healthcare practitioners, and infectious disease researchers. Given the flexibility in BioVaxys' viral vaccine platform based on haptenizing viral antigens, the Company is exploring the potential for producing a multivalent vaccine, which will be a combination of the haptenized spike proteins subunits from each clinically significant variant. BioVaxys Technology Corp.
shares C.BIOV are trading up 5 cents at $0.61.
